

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

NCT06834035

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	M. Peter Marinkovich
Enrollment	8 participants

Key Eligibility Criteria

Inclusion (6)

- Diagnosis of generalized Recessive dystrophic epidermolysis bullosa (RDEB) demonstrated by COL7A1 mutations.
- Diagnosis of EBA demonstrated by the presence of levels of serum C7 antibodies above the normal ELISA range
- Baseline skin blistering greater than 5% total body surface area
- wound at least 20 cm² able to be entirely treated with Vyjuvek weekly
- wound at least 20 cm² that has never been treated with Vyjuvek
- ... and 1 more (see full listing online)

Exclusion (4)

- History of thrombotic event(s)
- History of cardiac failure
- History of renal failure
- IgA deficiency

Locations (1 total)

Stanford University, Redwood City, California, United States